tetano
Editor, Senior Moderator
Int J Pharm
. 2023 Jun 21;123155.
doi: 10.1016/j.ijpharm.2023.123155. Online ahead of print. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles
Ji Wang[SUP] 1 [/SUP], Yanhao Zhang[SUP] 1 [/SUP], Shuo Dong[SUP] 1 [/SUP], Wenhui Zha[SUP] 1 [/SUP], Chao Liu[SUP] 1 [/SUP], Yang Wang[SUP] 1 [/SUP], Yuhao Jiang[SUP] 1 [/SUP], Hanlei Xing[SUP] 1 [/SUP], Xinsong Li[SUP] 2 [/SUP]
Affiliations
Lipid nanoparticles (LNPs)-based mRNA vaccines have shown great potential in the fight against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. However, it remains still a challenge to improve the delivery efficiency of LNPs and the long-term stability of their mediated mRNA vaccines. Herein, a novel ionizable lipid 2-hexyldecyl 6-(ethyl(3-((2-hexyldecyl)oxy)-2-hydroxypropyl)amino)hexanoate (HEAH) derived LNPs were developed for delivering the receptor binding domain (RBD) mRNAs. In vitro cell assays confirmed that the ionizable lipid HEAH with one ether bond and one ester bond derived LNPs possessed higher mRNA delivery efficiency compared with the approved ALC-0315 with two ester bonds used in the BNT162b2 vaccine. Notably, the HEAH-derived LNPs powder lyophilized did not significantly change for 30 days after storage at 37 °C indicating good thermostability. After two RBD mRNAs of Delta and Omicron variants were encapsulated into the HEAH-derived LNPs, a bivalent mRNA vaccine was obtained as a nanoparticle formulation. Importantly, the bivalent mRNA vaccine not only resisted Delta and Omicron and also generated protective antibodies against ancestral SARS-CoV-2. The HEAH-mediated bivalent vaccine induced stronger humoral and cellular immunity than those of the ALC-0315 group. Taken together, the ionizable lipid HEAH-derived LNPs show outstanding potential in improving the delivery efficiency of mRNA and the stability of mRNA vaccine.
Keywords: SARS-CoV-2; ionizable lipid; mRNA vaccine; thermostability; variant.
. 2023 Jun 21;123155.
doi: 10.1016/j.ijpharm.2023.123155. Online ahead of print. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles
Ji Wang[SUP] 1 [/SUP], Yanhao Zhang[SUP] 1 [/SUP], Shuo Dong[SUP] 1 [/SUP], Wenhui Zha[SUP] 1 [/SUP], Chao Liu[SUP] 1 [/SUP], Yang Wang[SUP] 1 [/SUP], Yuhao Jiang[SUP] 1 [/SUP], Hanlei Xing[SUP] 1 [/SUP], Xinsong Li[SUP] 2 [/SUP]
Affiliations
- PMID: 37402442
- DOI: 10.1016/j.ijpharm.2023.123155
Lipid nanoparticles (LNPs)-based mRNA vaccines have shown great potential in the fight against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. However, it remains still a challenge to improve the delivery efficiency of LNPs and the long-term stability of their mediated mRNA vaccines. Herein, a novel ionizable lipid 2-hexyldecyl 6-(ethyl(3-((2-hexyldecyl)oxy)-2-hydroxypropyl)amino)hexanoate (HEAH) derived LNPs were developed for delivering the receptor binding domain (RBD) mRNAs. In vitro cell assays confirmed that the ionizable lipid HEAH with one ether bond and one ester bond derived LNPs possessed higher mRNA delivery efficiency compared with the approved ALC-0315 with two ester bonds used in the BNT162b2 vaccine. Notably, the HEAH-derived LNPs powder lyophilized did not significantly change for 30 days after storage at 37 °C indicating good thermostability. After two RBD mRNAs of Delta and Omicron variants were encapsulated into the HEAH-derived LNPs, a bivalent mRNA vaccine was obtained as a nanoparticle formulation. Importantly, the bivalent mRNA vaccine not only resisted Delta and Omicron and also generated protective antibodies against ancestral SARS-CoV-2. The HEAH-mediated bivalent vaccine induced stronger humoral and cellular immunity than those of the ALC-0315 group. Taken together, the ionizable lipid HEAH-derived LNPs show outstanding potential in improving the delivery efficiency of mRNA and the stability of mRNA vaccine.
Keywords: SARS-CoV-2; ionizable lipid; mRNA vaccine; thermostability; variant.